Sales growth is slowing, and there's an issue with one of the biotech's pipeline drugs.
News & Analysis: Regeneron Pharmaceuticals
This big-cap biotech has a problem or two on its hands.
REGN earnings call for the period ending March 31, 2019.
The big biotech disappointed investors in the first quarter with slower-than-expected revenue and earnings growth. Here's what you need to know.
Which stock wins in a battle between these two successful biotechs?
These drugmakers' profit margins are sky-high. But does that necessarily mean they're great stocks to buy?
REGN earnings call for the period ending December 31, 2018.
Biotech may be a tough industry to invest in, but we've found three companies within that space that are worth looking into.
Can the sizzling momentum continue for these high-flying healthcare stocks?
Key trials suggest doctors may change how they treat patients with cardiovascular disease.